Vetgrad logo
VetGrad Ask An Expert Sign in Register for FREE Forum Competition VetGrad Offers Contact Us
Search
Powered by Google
Latest News
Home

Home

10 Minute Top Up

CPD

Resources

How To

YVN

Need to Know

Jobs

Oops

PDP/PDR

Why Bother?


Ask An Expert

Sign in

Register for FREE

Forum

Competition

VetGrad Offers

Contact Us

Ceva enters European swine vaccine market with new, targeted vaccine to improve control of enzootic pneumoniae 

A brand new vaccine, Hyogen, launched by Ceva Sante Animale will help to improve the welfare of European pigs. The vaccine which protects against Mycoplasma hyopneumoniae, uses a unique field relevant strain and novel adjuvant that can boost innate and adaptive immunity.

With 90% of swine farms worldwide affected by respiratory disease and an urgent need to preserve the future of antibiotics by reducing the previous practice of prophylactic use, the adoption of targeted, preventative health programmes has become even more critical.

Hyogen provides superior protection against the respiratory infection caused by Mycoplasma hyopneumoniae bacteria. The one shot application at weaning makes it easy to administer and as a killed bacterial vaccine combined with a potent adjuvant, it confers the longest protection of up to 26 weeks, throughout the entire fattening period.  Not all vaccines currently available in Europe, are able to achieve this leaving pigs vitally exposed at critical times in the growth cycle.

Ceva began extensive in - field research of a practical tool to support use of the vaccine with the launch of the Ceva Lung Programme in Asia 2 years ago and now in Europe.  Respiratory experts developed the programme, which was then simplified into practical guidelines and an easy-to-use iPad and Android app, which have made it much easier to evaluate the presence and impact of the main respiratory pathogens on farms and in the slaughterhouse. As a result, it is much easier to target vaccination according to individual herd requirements.

In some European countries, investigated herds had a 100% infection rate of Mycoplasma hyopneumoniae, this level of infection can prolong the time to slaughter weight by 5.6 days.  Following its rapid rise into the top 3 global poultry vaccine and equipment suppliers, Ceva decided to concentrate its swine research on respiratory health, an area where it felt it could have most significant benefit for producers.

The symposium that began in Barcelona on Friday brings together swine experts from around the world to discuss the need for better preventative respiratory health on farms and present the scientific benefits of the new vaccine. Dr. Stefano Gozio, Head of Ceva’s Swine business said:

“We need to create partnerships with expert veterinarians if we are to achieve better preventative respiratory health on farms. This was the objective of our symposium; we believe that more sharing of knowledge between professionals – producers and veterinarians through tools such as the Ceva Lung programme is the future for our industry.”

Follow us:
Share this page: